Community Oncology Alliance (COA) submitted formal comments to CMS in support of proposed changes to the 340B Drug Discount Program and site-neutral paymnts put forward in the Hospital Outpatient Prospective Payment (HOPPS) rule. However, they also submitted comments warning against proposals to introduce new third-party middlemen to the Part B system.
The Community Oncology Alliance (COA) submitted formal comments to CMS in support of the agency's proposed additional changes to the 340B Drug Discount Program. They also voiced support for the site-neutral payments proposed in the Hospital Outpatient Prospective Payment (HOPSS) rule for 2019, which they say will address "tremendous Medicare Part B spending increases that have resulted from the growing shift of care from independent community practices to hospital outpatient departments."
However, COA did caution against proposals for introducing new third-party middlemen to the Part B system, saying it would have a negative impact on patient care.
Read the comments in full here.
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen